Results 91 to 100 of about 110,931 (189)

Bevacizumab in the treatment of HER2-negative breast cancer

, 2008
Vito LorussoOncologic Institute, Vito Fazzi Hospital, Lecce, ItalyAbstract: Angiogenesis has a clear and definite role in the breast cancer progression process, making antivascular endothelial growth factor (VEGF) therapies an attractive option for the ...
Vito Lorusso
core  

Critical appraisal of bevacizumab in the treatment of ovarian cancer

, 2015
Hiroyuki Yoshida, Akira Yabuno, Keiichi FujiwaraDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, JapanAbstract: Bevacizumab is the first molecular-targeted agent to be used for the treatment of
Fujiwara K, Yabuno A, Yoshida H
core  

Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma

, 2011
Mohammad-Reza Sedghipour, Ali Mostafaei, Yousef TaghaviNikoukari Ophthalmology University Hospital, Tabriz University of Medical Sciences, Tabriz, IranBackground: The purpose of this study was to assess the effect of bevacizumab in maintaining ...
Taghavi Y, Sedghipour MR, Mostafaei A
core  

Cancer therapy and cardiovascular risk: focus on bevacizumab

, 2015
Panagiota Economopoulou,1 Athanasios Kotsakis,2 Ioannis Kapiris,3 Nikolaos Kentepozidis3 1Medical Oncology Unit, 2nd Department of Internal Medicine, Attikon University Hospital, Haidari, Athens, 2Department of Medical Oncology, University Hospital of ...
Kotsakis A, Kapiris I, Economopoulou P, Kentepozidis N   +3 more
core  

Role of bevacizumab therapy in the management of glioblastoma

, 2010
Scott J Peak, Victor A LevinNeuro-Oncology Program, Department of Neurosurgery and Neuroscience, Kaiser Permanente, Redwood City, CA, USAAbstract: Glioblastoma is one of the most common primary brain tumors and one of the most difficult to treat.
Victor A Levin, Scott J Peak
core  

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis

, 2018
Tomas Buchler,1 Renata Chloupkova,2 Alexandr Poprach,3 Ondrej Fiala,4,5 Igor Kiss,3 Katerina Kopeckova,6 Ladislav Dusek,2 Veronika Veskrnova,1 Lubomir Slavicek,7 Milan Kohoutek,8 Jindrich Finek,4 Marek Svoboda,3 Lubos Petruzelka,9 Bohuslav Melichar10 ...
Buchler T, Finek J, Dusek L, Fiala O, Poprach A, Kohoutek M, Veskrnova V, Slavicek L, Kopeckova K, Melichar B, Svoboda M, Kiss I, Chloupkova R, Petruzelka L   +13 more
core  

Vascular Targeted Agents for the Treatment of Angiosarcoma [PDF]

, 2013
Background: Angiogenesis is the process of new blood vessel formation, and is regulated by angiogenic growth factors including vascular endothelial growth factor (VEGF). Angiosarcomas are rare, aggressive vascular tumours.
Young, Robin
core  

Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases

, 2013
GJM Herder,1 H Codrington,2 CD Colder,3 JG Aerts4,51St Antonius Hospital, Nieuwegein, The Netherlands; 2Haga Hospital, The Hague, The Netherlands; 3St Jansdal Hospital, Harderwijk, The Netherlands; 4Amphia Hospital, Breda; 5Erasmus MC Rotterdam, The ...
Aerts JG, Colder CD, Codrington H, Herder GJM   +3 more
core  

Advanced Coats’ disease treated with intravitreal bevacizumab combined with laser vascular ablation

, 2014
Victor M Villegas,1 Aaron S Gold,1 Audina M Berrocal,2 Timothy G Murray11Ocular Oncology and Retina, Miami, FL, USA; 2Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, FL, USAPurpose: To ...
Berrocal AM, Villegas VM, Gold AS, Murray TG   +3 more
core  

Impact of light-induced stress on Bevacizumab (Avastin®) during handling in hospital pharmacy: implication on the biological activity

reservedA partire dal 1986, anno dell’immissione in commercio del primo anticorpo monoclonale ad uso terapeutico, si è verificato un notevole incremento nel numero di farmaci appartenenti a questa classe approvati dall’EMA e dall’FDA.
SOTTORIVA, CHIARA
core